Clinical Trial Detail

NCT ID NCT04291664
Title PK and Dose Escalation and Expansion Study of DST-2970
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors DisperSol Technologies, LLC
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Prednisone

DST-2970 + Prednisone

Age Groups: senior adult

No variant requirements are available.